Silver Sponsor

MolMed is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative Cell&Gene based therapies. MolMed’s pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK), a cell-based therapy enabling bone marrow transplants from partially compatible donors currently in Phase III in high-risk acute leukaemia and granted a CMA by the European Commission; CARCD44v6, an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development; NGR-hTNF, a therapeutic agent for solid tumours investigated in a broad clinical program involving more than 1,000 patients. Thanks to its GMP manufacturing capacity of 4800 sqm, MolMed also offers a wide range of Cell&Gene therapy activities for leading EU/US companies. MolMed is headquartered in Milan at the San Raffaele DIBIT, has an operating unit at OpenZone in Bresso and it is listed on the main market (MTA) of the Milan stock exchange.


The World Advanced Therapies and Regenerative Medicine Congress and Exhibition is an international conference and exhibition featuring the latest in advanced therapies, bioengineering and surrounding technology. To attend the conference which features global leaders in the biopharma and regenerative medicine industries, there is a registration fee. The exhibition is free to visit.

Register your pass here.